# Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

> **NCT00895739** · PHASE2 · UNKNOWN · sponsor: **Federico II University** · enrollment: 50 (estimated)

## Conditions studied

- Nonmalignant Neoplasm

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT00895739
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895739, "Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00895739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*